Abstract
The presence of Galanin and Neuropeptide Y and/or their receptors in several areas of the brain involved in memory, mood, cardiovascular control and food intake indicates that Galanin, and Neuropeptide Y could equilibrate the physiological actions of each other. There is evidence for the existence of interactions between Galanin Receptor and Neuropeptide Y Receptor in the nucleus of the solitarii tract (NTS), hypothalamus and dorsal raphe nucleus probably taking place with the formation of heteromers between Galanin Receptor and Neuropeptide Y Y1 Receptor. The galanin fragment (Gal 1-15) preferring receptors may instead be formed by the GalR1-GalR2 heteromer which in the NTS may interact with Neuropeptide Y Y2 receptors. These receptor heteromers may be one key molecular mechanism for Galanin and its N-terminal fragment (Galanin 1-15) to modulate the function of different types of glia–neuronal networks in the CNS, especially the emotional, metabolic and cardiovascular networks.
Keywords: Galanin, Galanin 1-15, Galanin receptor subtypes, GPCRs, Heteromers, Neuropeptide Y, NPY receptors.
Current Protein & Peptide Science
Title:Galanin Receptor/Neuropeptide Y Receptor Interactions in the Central Nervous System
Volume: 15 Issue: 7
Author(s): Zaida Diaz-Cabiale, Antonio Flores-Burgess, Concepcion Parrado, Manuel Narvaez, Carmelo Millon, Araceli Puigcerver, Rafael Covenas, Kjell Fuxe and Jose A. Narvaez
Affiliation:
Keywords: Galanin, Galanin 1-15, Galanin receptor subtypes, GPCRs, Heteromers, Neuropeptide Y, NPY receptors.
Abstract: The presence of Galanin and Neuropeptide Y and/or their receptors in several areas of the brain involved in memory, mood, cardiovascular control and food intake indicates that Galanin, and Neuropeptide Y could equilibrate the physiological actions of each other. There is evidence for the existence of interactions between Galanin Receptor and Neuropeptide Y Receptor in the nucleus of the solitarii tract (NTS), hypothalamus and dorsal raphe nucleus probably taking place with the formation of heteromers between Galanin Receptor and Neuropeptide Y Y1 Receptor. The galanin fragment (Gal 1-15) preferring receptors may instead be formed by the GalR1-GalR2 heteromer which in the NTS may interact with Neuropeptide Y Y2 receptors. These receptor heteromers may be one key molecular mechanism for Galanin and its N-terminal fragment (Galanin 1-15) to modulate the function of different types of glia–neuronal networks in the CNS, especially the emotional, metabolic and cardiovascular networks.
Export Options
About this article
Cite this article as:
Diaz-Cabiale Zaida, Flores-Burgess Antonio, Parrado Concepcion, Narvaez Manuel, Millon Carmelo, Puigcerver Araceli, Covenas Rafael, Fuxe Kjell and Narvaez A. Jose, Galanin Receptor/Neuropeptide Y Receptor Interactions in the Central Nervous System, Current Protein & Peptide Science 2014; 15 (7) . https://dx.doi.org/10.2174/1389203715666140901111709
DOI https://dx.doi.org/10.2174/1389203715666140901111709 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report
Current Drug Safety Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Structure – Activity Relationships of PDE5 Inhibitors (Supporting Material)
Current Medicinal Chemistry Oleic Acid Vesicles for Transdermal Delivery of Propranolol Hydrochloride: Development and Characterization
Current Drug Therapy On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Design, Synthesis and Biological Evaluation of Some Oxadiazole Derivatives as Novel Amide-Based Inhibitors of Soluble Epoxide Hydrolase
Letters in Drug Design & Discovery Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Promising Therapies in Sickle Cell Disease
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Regional Editor:
Current Organic Chemistry Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Current Diabetes Reviews Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews Apoptosis Modulated by Oxidative Stress and Inflammation During Obstructive Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued)